Scilex Holding Company (SCLX) has provided an announcement.
Scilex Holding Company is considering a strategic move to boost the value of its subsidiary, Semnur Pharmaceuticals, and its product candidate, SEMDEXA™. The Board of Directors has given the green light to investigate various options, such as a spin-off, merger, or other transactions, with the goal of enhancing stockholder returns. This initiative represents a proactive approach to capitalize on the subsidiary’s assets and potential.
See more insights into SCLX stock on TipRanks’ Stock Analysis page.
